Incyte
INCY
C$93.11
Share price
0.41%
Change (1 day)
19.08%
Change (1 year)
Categories
Incyte (INCY) - Total debt
Total debt on the balance sheet as of March 2025 : C$58.65 Million
According to Incyte's latest financial reports the company's total debt is C$58.65 Million. A company’s total debt is the sum of all current and non-current debts.
Incyte - Total debt on balance sheet (from 1996 to 2025)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2024-12-31 | C$62.48 M | 23.05% |
| 2023-12-31 | C$50.78 M | -9.73% |
| 2022-12-31 | C$56.25 M | -1.52% |
| 2021-12-31 | C$57.12 M | -5.75% |
| 2020-12-31 | C$60.6 M | -22.95% |
| 2019-12-31 | C$78.65 M | 59.82% |
| 2018-12-31 | C$49.21 M | 63.1% |
| 2017-12-31 | C$30.17 M | -96.55% |
| 2016-12-31 | C$0.87 B | 1.81% |
| 2015-12-31 | C$0.85 B | 9.75% |
| 2014-12-31 | C$0.78 B | 11.26% |
| 2013-12-31 | C$0.70 B | 113.91% |
| 2012-12-31 | C$0.32 B | 2.37% |
| 2011-12-31 | C$0.32 B | 9.64% |
| 2010-12-31 | C$0.29 B | -37.09% |
| 2009-12-31 | C$0.46 B | -3.2% |
| 2008-12-31 | C$0.48 B | 24.91% |
| 2007-12-31 | C$0.38 B | -10.75% |
| 2006-12-31 | C$0.43 B | 8.56% |
| 2005-12-31 | C$0.39 B | -12.51% |
| 2004-12-31 | C$0.45 B | 109.02% |
| 2003-12-31 | C$0.21 B | -19.9% |
| 2002-12-31 | C$0.27 B | -4.85% |
| 2001-12-31 | C$0.28 B | 1.48% |
| 2000-12-31 | C$0.28 B | 97447.28% |
| 1999-12-31 | C$0.28 M | -76.55% |
| 1998-12-31 | C$1.23 M | |
| 1996-12-31 | C$0.13 M |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 Amgen AMGN | C$78.05 B | 132,975.91% | 🇺🇸 USA |
 Ligand Pharmaceuticals LGND | C$6.05 M | -89.68% | 🇺🇸 USA |
 Eli Lilly LLY | C$52.39 B | 89,224.66% | 🇺🇸 USA |
 Pfizer PFE | C$83.37 B | 142,043.83% | 🇺🇸 USA |
 Geron GERN | C$0.16 B | 182.42% | 🇺🇸 USA |
 Ardelyx ARDX | C$0.21 B | 259.72% | 🇺🇸 USA |
 Novartis NVS | C$42.53 B | 72,420.23% | 🇨🇭 Switzerland |
 AVEO Oncology
AVEO | C$52.61 M | -10.29% | 🇺🇸 USA |
 CTI BioPharma
CTIC | C$66.51 M | 13.40% | 🇺🇸 USA |